Nutraceutical Improves Glycemic Control, Insulin Sensitivity, and Oxidative Stress in Hyperglycemic Subjects: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
| Autor: | Patcharanee Pavadhgul, Akkarach Bumrungpert, Rewadee Chongsuwat, Surat Komindr |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
030209 endocrinology & metabolism Plant Science Pharmacology Placebo medicine.disease_cause 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Insulin resistance Nutraceutical Drug Discovery Hyperlipidemia medicine Glycemic 030109 nutrition & dietetics business.industry General Medicine medicine.disease Clinical trial Complementary and alternative medicine chemistry Cholecalciferol business Oxidative stress |
| Zdroj: | Natural Product Communications. 15:1934578X2091868 |
| ISSN: | 1555-9475 1934-578X |
| DOI: | 10.1177/1934578x20918687 |
| Popis: | The aim of this research was to investigate the effects of nutraceuticals including bitter melon, fenugreek, cinnamon, alpha-lipoic acid, zinc, biotin, chromium, and cholecalciferol on glycemic control, insulin sensitivity, lipid profiles, oxidative stress, and inflammatory markers in hyperglycemia. The study design was a randomized, double-blind, placebo-controlled trial. Subjects with hyperglycemia were randomly divided into 2 groups. The treatment group ( n = 52) was given a nutraceutical and the control group ( n = 50) was provided with a placebo for 12 weeks. Fasting blood glucose (FBG), hemoglobin A1c (HbA1C), homeostatic model assessment of insulin resistance (HOMA-IR), lipid profiles, biomarkers of oxidative stress, and inflammation were assessed before and after the intervention at 6 weeks and 12 weeks. Nutraceutical supplementation demonstrated a statistically significant decrease in FBG (13.4% and 18.9%), HbA1C (6.5% and 11.3%), and HOMA-IR (28.9% and 35.2%) compared with the placebo. Moreover, low-density lipoprotein-cholesterol (LDL-C) level was significantly reduced in the nutraceutical group (7.1% and 9.3%). Furthermore, the nutraceutical significantly decreased oxidative stress markers, oxidized LDL-C (14.8% and 18.9%) and malondialdehyde (16.6% and 26.2%) compared with the placebo. In conclusion, this nutraceutical can improve glycemic control, insulin resistance, lipid profiles, and oxidative stress markers in hyperglycemic subjects. Therefore, it has the potential to decrease cardiovascular disease risk factors. Clinical trial registration: TCTR20180907001, www.clinicaltrials.in.th. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|